Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma

Japanese Journal of Clinical Oncology

Volumn 36, Issue 7, 2006, Pages 432-438

  Eom, Ki Seong ^a   Min, Chang Ki ^a   Lee, Seok ^a   Kim, Yoo Jin ^a   Kim, Sung Yong ^a   Kim, Hee Je ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Kim, Chun Choo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Autologous stem cell transplantation; Multiple myeloma; Reduced intensity allogeneic transplantation; Tandem stem cell transplantation

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE LESION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; FEMALE; FEVER; FOLLOW UP; GENDER; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; REDUCED INTENSITY CONDITIONING; RETREATMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33748122377     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl041     Document Type: Article

References (35)

1. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
2. Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 2827-33.
3. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, et al. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-6.
4. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein, KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-54.
5. Kröger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-60.
6. Attal M, Harousseau JL, Facon T, Guilhot, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-502.
7. Chronic Leukemia-Myeloma Task Force. National Cancer Institute. Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 145-58.
8. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089-93.
9. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
10. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-7.
11. Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: Impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003; 32: 1145-51.
12. Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, et al. Chronic Leukaemia Working Party Myeloma Subcommittee, European Group for Blood and Marrow Transplantation. Benefit and timing of second transplantations in multiple myeloma: Clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol. 2004; 22: 1674-81.
13. Putkonen M, Rauhala A, Itala M, Kauppila M, Pelliniemi TT, Remes K. Double versus single autotransplantation in multiple myeloma; a single center experience of 100 patients. Haematologica 2005; 90: 562-3.
14. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 35: 1860-73.
15. Le Blanc R, Montminy-Metivier S, Belanger R, Busque L, Fish D, Roy DC, et al. Allogeneic transplantation for multiple myeloma: Further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001; 28: 841-8.
16. Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J. Donor lymphocyte infusions for multiple myeloma: Clinical results and novel perspectives. Bone Marrow Transplant 2004; 34: 923-8.
17. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474-80.
18. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-7.
19. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-10.
20. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999; 93: 55-65.
21. Barlogie B, Desikan R, Munshi N, Badros A, Shaughnessy J, Epstein J, et al. Durable CR in multiple myeloma (MM) in the absence of chromosome 13 deletion and with tandem melphalan-based high-dose therapy (HDT). The Arkansas experience with 1,000 consecutive patients. Blood 1999; 94(Suppl. 1): 714a.
22. Alexanian R, Weber D, Delasalle K, Dimopoulous M, Giralt S, Champlin R, et al. Impact of complete remission after ablative therapy for multiple myeloma. Blood 1999; 94(Suppl. 1): 124a.
23. Lahuerta JJ, Grande C, Martinez-Lopez J, De La Serna J, Toscano R, Ortiz MC, et al. Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea phase II trial. Br J Haematol 2003; 120: 296-303.
24. Lemoli RM, Martinelli G, Zamagni E, Motta MR, Rizzi S, Terragna C, et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood 2000; 95: 2234-9.
25. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-5.
26. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, et al. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant 1999; 23: 1261-6.
27. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979-83.
28. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
29. Singhal S, Mehra J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71.
30. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
31. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-72.
32. Attal M, Harousseau J, Leyvraz S, Chantal D, Cyrille H, Lofti B, et al. Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02). [Abstract 535] Blood 2004; 104.
33. Zomas A, Stefanoudaki K, Fisfis M, Papadaki T, Mehta J. Graft-versus-myeloma after donor leukocyte infusion: Maintenance of marrow remission but exramedullary relapse with plasmacytomas. Bone Marrow Transplant 1998; 21: 1163-5.
34. Rondelli D, Bandini G, Cavo M, Re F, Motta M, Senese B, et al. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: A case report. Bone Marrow Transplant 1999; 24: 685-7.
35. Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005; 90: 278-9.